OMGAQ — Omega Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.11m
- -$12.68m
- $3.09m
Annual income statement for Omega Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 2.07 | 3.09 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17.3 | 28.6 | 66.2 | 105 | 103 |
| Operating Profit | -17.3 | -28.6 | -66.2 | -103 | -100 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.9 | -29.4 | -68.3 | -103 | -97.4 |
| Net Income After Taxes | -17.9 | -29.4 | -68.3 | -103 | -97.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.9 | -29.4 | -68.3 | -103 | -97.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.9 | -29.4 | -68.3 | -103 | -97.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.384 | -0.63 | -3.05 | -2.14 | -1.8 |